Particle.news
Download on the App Store
27 ARTICLES
·
last wk.

Weight-Loss Drugs Linked to 41% Reduction in Obesity-Related Cancer Risk

New research presented at the European Congress on Obesity highlights the potential of GLP-1 receptor agonists to prevent obesity-related cancers, surpassing the protective effects of bariatric surgery.

Image
Image
Image

Overview

  • A study published in eClinicalMedicine found that GLP-1 receptor agonists reduced obesity-related cancer risk by 41% compared to bariatric surgery, which lowers risk by 30–42%.
  • Experts suggest the anti-cancer effects of GLP-1 drugs stem from mechanisms such as reducing inflammation and enhancing immune responses against tumor cells.
  • The University of Manchester, supported by Cancer Research UK, is planning a large-scale clinical trial within three to five years to validate these findings and assess broader implications.
  • The study analyzed health data from over 6,000 patients and showed similar cancer prevention rates for GLP-1 drugs and bariatric surgery, despite greater weight loss in surgery patients.
  • Researchers emphasize the need for randomized trials to confirm the benefits and rule out potential risks, particularly for non-obesity-related cancers.